We specialize in accelerating the journey of novel biological therapeutics from concept to clinic. We offer comprehensive, integrated solutions tailored to the unique challenges of viral vector platforms. Within our specialized Viral Vector CDMO Solutions, our dedicated capabilities for modified vaccinia ankara (MVA) stand out, providing partners with the scientific depth and GMP infrastructure necessary to navigate the complexities of this powerful vector system efficiently and reliably. Explore our broader capabilities in CDMO Solutions.
Overview of Modified Vaccinia Ankara (MVA)
MVA represents a highly attenuated strain of vaccinia virus, extensively passaged in avian cells, resulting in significant genomic deletions that render it replication-deficient in mammalian cells. This inherent safety profile, combined with its large packaging capacity (~25 kb), robust immunogenicity, and ability to accommodate complex transgenes, makes MVA an exceptionally versatile vector platform. It excels in eliciting potent humoral and cellular immune responses, positioning it as a leading candidate for diverse prophylactic and therapeutic applications, including next-generation vaccine development and targeted immunotherapies. Unlike replication-competent vectors, MVA's inability to replicate in human hosts minimizes safety concerns while maintaining high-level, transient transgene expression essential for efficacy. Its stability and well-characterized history further enhance its appeal for clinical development.
Fig.1 Design, construction, and virological in vitro characterization of sfMVA-mCherry (MVA-mCherry) and sfMVA-GFP (MVA-GFP). (Tscherne, et al., 2024)
Our MVA CDMO Solutions
We provide end-to-end support for MVA-based programs, from initial vector design through manufacturing. Our deep virological expertise and state-of-the-art facilities are dedicated to overcoming the specific hurdles associated with this poxvirus vector.
MVA Vector Design & Engineering
Our molecular biology team excels in the intricate design of MVA constructs. We leverage advanced bioinformatics tools and proprietary databases to optimize transgene insertion sites, select potent and tissue-specific promoters, and incorporate essential genetic elements for stability and high-yield expression. We engineer constructs for enhanced safety, immunogenicity, and manufacturability, utilizing seamless cloning techniques and rigorous sequence verification. Our design philosophy prioritizes both therapeutic efficacy and downstream process scalability.
Cell Line Development & Banking
Successful MVA production hinges on robust avian cell substrates. We offer comprehensive services including cell line screening, adaptation for suspension culture, and generation of fully characterized master and working cell banks. Our cell banking processes adhere strictly to ICH Q5D guidelines, ensuring identity, purity, viability, and freedom from adventitious agents, providing a solid foundation for consistent production.
Upstream Process Development & Intensification
Developing a high-titer, scalable MVA upstream process requires specialized knowledge. We optimize every parameter: infection strategies, culture conditions, bioreactor operation modes, and process analytical technology (PAT) integration. Our focus is on achieving maximum infectious titer while maintaining vector quality, employing scale-down models to rapidly translate findings to pilot and production scales. We pioneer process intensification strategies to significantly increase volumetric productivity.
Downstream Purification Process Development
Purifying large, enveloped MVA particles presents distinct challenges. Our team designs and develops robust, scalable purification trains tailored to MVA's properties. This includes clarification (depth filtration, centrifugation), nuclease treatment, and multi-step chromatography, followed by ultrafiltration/diafiltration (UF/DF) for concentration and buffer exchange. We prioritize methods maximizing recovery of infectious virus, removing host cell DNA/proteins, and achieving required purity levels, all while ensuring process robustness.
Analytical Method Development & Characterization
Rigorous analytics are paramount. We develop, qualify, and validate a comprehensive panel of MVA-specific assays. This includes potency assays (e.g., immunostaining plaque assays, TCID50), titer determination (physical/genomic vs. infectious), identity (PCR, sequencing), purity (SDS-PAGE, HPLC for residuals, HCP, DNA), safety (sterility, mycoplasma, endotoxin, adventitious agents), and comprehensive characterization (electron microscopy, genomic integrity).
Manufacturing
We provide large-scale MVA manufacturing. Our manufacturing services encompass pilot and batch production, in-process monitoring, batch release testing, and full regulatory compliance. We ensure consistent product quality, scalable processes from early-phase studies, and robust process control, providing end-to-end solutions from concept to patient-ready virus products.
We stand ready to leverage our specialized expertise and GMP infrastructure to accelerate your MVA-based program from concept to clinic. Whether you require tailored vector engineering, scalable process development, or end-to-end cGMP manufacturing, our team delivers scientifically rigorous solutions designed to overcome the unique challenges. Partner with us to advance your innovative candidates with confidence.
Reference
- Tscherne, A.; et al. Rapid development of modified vaccinia virus ankara (MVA)-based vaccine candidates against marburg virus suitable for clinical use in humans. Vaccines. 2024, 12(12): 1316.
Our products and services are for research use only.
